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Intellectual disability (ID) disorders are genetically and phenotypically highly heterogeneous and present a major challenge in clinical
genetics andmedicine. Althoughmany genes involved in ID have been identified, the etiology is unknown inmost affected individuals.
Moreover, the function ofmost genes associatedwith ID remains poorly characterized. Evidence is accumulating that the control of gene
transcription through epigenetic modification of chromatin structure in neurons has an important role in cognitive processes and in the
etiology of ID. However, our understanding of the keymolecular players andmechanisms in this process is highly fragmentary. Here, we
identify a chromatin-modification module that underlies a recognizable form of ID, the Kleefstra syndrome phenotypic spectrum (KSS).
In a cohort of KSS individuals without mutations in EHMT1 (the only gene known to be disrupted in KSS until now), we identified
de novo mutations in four genes, MBD5, MLL3, SMARCB1, and NR1I3, all of which encode epigenetic regulators. Using Drosophila,
we demonstrate that MBD5, MLL3, and NR1I3 cooperate with EHMT1, whereas SMARCB1 is known to directly interact with MLL3.
We propose a highly conserved epigenetic network that underlies cognition in health and disease. This network should allow the design
of strategies to treat the growing group of ID pathologies that are caused by epigenetic defects.Introduction
Intellectual disability (ID) disorders affect about 1%–3% of
the western population and are genetically and phenotyp-
ically highly heterogeneous. Mutations in more than 400
genes have been identified, yet the genetic cause remains
unknown in the majority of individuals with ID.1 The
genetic and phenotypic heterogeneity of IDmakes concep-
tualizing strategies for treatment difficult. However,
a number of genes that cause ID appear to act in common
molecular and cellular pathways, raising the possibility
that a group of genetically heterogeneous individuals
with ID could be treated if a common molecular etiology
were targeted.2 One of the emerging mechanisms that
appears to be important in ID is the regulation of neuronal
function through the epigenetic control of gene transcrip-
tion.3 Epigenetic modifications are important factors in
the regulation of cognition in animal models, and several
well-characterized ID disorders, such as Rett syndrome
(MIM 312750), Angelman syndrome (MIM 105830), and
Fragile X syndrome (MIM 300624), have a known epige-
netic origin.3,4 Here, we reveal a chromatin-modification
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spectrum (KSS [see Subjects and Methods]).
The core phenotype of Kleefstra syndrome (MIM
610253) comprises ID, childhood hypotonia, and distinc-
tive facial features.5–7 KSS can be caused by haploinsuffi-
ciency of EHMT1, which encodes a histonemethyltransfer-
ase capable of histone 3 lysine 9 dimethylation (H3K9me2)
in euchromatic regions of the genome.8,9 In our KSS
cohort, about 25% of individuals have EHMT1 loss-of-
function mutations.3 We hypothesized that the ‘‘EHMT1-
negative’’ individuals have mutations in genes that share
a biological function with EHMT1. Here, we report de
novo mutations in four functionally related genes in four
individuals with KSS, indicating that this subclass of ID is
caused by disruption of a common epigenetic module.Subjects and Methods
Subjects
We have collected a clinically defined cohort of individuals with
the core features of Kleefstra syndrome and have identified
EHMT1 loss-of-function mutations in 25% of these individuals.3
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Figure 1. Clinical Photographs and Mutation Information
(A–D) Photographs of individuals with KSS and chromatograms
comparing individuals with KSS to parents and/or siblings indicate
de novo occurrence for the four probably pathogenic mutations
identified. Mutations are highlighted in yellow.
(A) KS113 with MLL3 mutation c.4441C>T. Reverse-strand
sequences of individual KS113, the mother, and two healthy
sisters are shown. Note the midface hypoplasia, synophrys,
upward slant of palpebral fissures, and everted lower lip.
(B) KS47 with SMARCB1mutation c.110G>A, which is not present
in the parental DNA. Note the midface hypoplasia, upward slant
of the eyes, and tongue protrusion.
(C) KS78 with MBD5 mutation c.150del, which is not present in
the parental DNA. A reverse-strand sequence is shown. Note the
synophrys, upward slant of palpebral fissures, upturned nose
with broad tip, full lips, and everted lower lip.
(D) KS220withNR1I3mutation c.740T>C, which is not present in
the parental DNA. Reverse-strand sequences are shown. Note the
midface hypoplasia, short upturned nose, everted lower lip, and
pointed chin.
(E) Four KSS individuals (KS1, KS2, KS245, and KS21) with previ-
ously published6,7,10 EHMT1 defects show a close resemblance of
facial characteristics to the four individuals in (A)–(D).
74 The American Journal of Human Genetics 91, 73–82, July 13, 2012heterogeneity for certain features (e.g., renal anomalies and
hearing loss) and significant clinical overlap with other related
syndromes, such as Smith-Magenis syndrome (MIM 182290).
Therefore, we refer to this group of related phenotypes as KSS.
From this study population, we selected nine cases who were
found to be negative for EHMT1 defects and who were previously
screened for pathogenic copy-number variants (CNVs) by high-
density microarray platforms (Affymetrix 250K microarray equiv-
alentorhigher resolution). Informed consentwasobtained fromall
individuals and their parents after approval for the research project
was obtained from the institutional ethical board at Radboud
University Nijmegen Medical Centre, Commissie Mensgebonden
Onderzoek Regio Arnhem-Nijmegen (NL36191.091.11). In this
study, we identified de novo mutations in four individuals
(Figure 1). General information on medical and developmental
characteristics of these four individuals is given below, and their
clinical characteristics are compared with those of KSS individuals
with EHMT1mutations in Table 1.
Individual KS113 was born with a normal birth weight after
a normal pregnancy and delivery to nonconsanguineous healthy
parents. She walked independently at the age of 19 months but
never developed speech. She gradually developed problematic
behavior with periods of hyperactivity and aggressiveness. Her
total intelligence quotient (TIQ) was 35. At the age of 15 years,
she had a height of 148 cm (2.5 standard deviations [SDs]),
a weight of 41 kg (0 SDs), and an occipitofrontal circumference
(OFC) of 52 cm (2 SDs). Additional examinations, including
a metabolic screen of blood and urine and DNA analysis of RAI1,
revealed no abnormalities.
Individual KS47, the second child of healthy nonconsanguine-
ous parents, was born at 36 weeks of gestation after a normal preg-
nancy with a birth weight of 2,400 g, a length of 49 cm, and head
circumference of 33.5 cm. Neonatally, Down syndrome (MIM
190685) was suspected. At the age of 2.5 years, she was shunted
for hydrocephalus. At that age, she was not able to sit and did
not speak any words. Subsequently, she required multiple neuro-
surgical procedures for shunt problems because she had an abnor-
mally high production of cerebrospinal fluid as a result of
a chorioid plexus anomaly. A partial plexectomy was required,
and she has since been clinically stable. She had impaired visual
function, which was probably at least partially central in nature.
She is myopic (approximately 7 diopters bilaterally). She is
a generally sociable person who is interested in her surroundings.
At the age of 9.5 years, her height was 144 cm (0 SDs), her weight
was 31 kg (1 SD), and her head circumference was 52.4 cm
(0 SDs). No abnormalities were detected on a cardiac ultrasound,
a DNA analysis of UBE3A, a Southern blot for 15q11-q13, or stan-
dard cytogenetic karyotyping in both blood and fibroblasts.
Individual KS78 was born to healthy nonconsanguineous
parents. He has three normal siblings, and his 8-month-old
brother had laryngomalacia and macrocephaly. Vaginal delivery
was induced at 42 weeks of gestation because of a postdate preg-
nancy. His birth weight was 3,700 g. He had apnea and stridor
with laryngomalacia. He walked at 17 months and spoke only
single words until after age 3. He was treated with daily growth-
hormone injections for one year between the ages of 12 and
13 years, and this treatment resulted in amodest response of about
4 cm. Since then, he has grown only about 1 cm. He had a grand
mal seizure between the ages of 2 and 3, but since then, he has had
staring spells and mild electroencephalography (EEG) changes.
His TIQ was 69 at the age of 12 years. His behavior is characterized
by anxiety, a high pain tolerance, stereotypic and self-injurious
Table 1. Clinical Characteristics in Individuals with Different
Genetic Causes of KSS
Symptoms KS113 KS47 KS78 KS220
EHMT1
Defects
Sex female female male female
Intellectual disability þ þ þ þ 100%
Childhood hypotonia þ þ þ þ 100%
Microcephaly þ    20%
Short stature þ  þ þ 20%
Overweight     45%
Brachycephaly þ þ þ  40%
Midface hypoplasia þ þ þ þ 80%
Coarse facies þ þ þ  50%
Hypertelorism þ þ þ þ 30%
Synophrys þ þ þ  60%
Arched eyebrows   þ  30%
Short nose  þ þ þ 45%
Anteverted nostrils  þ þ þ 25%
Macroglossia
(protruding tongue)
 þ  þ 40%
Tented and cupid-bowed
upper lip
þ þ þ þ 25%
Thick and everted
lower lip
þ  þ þ 25%
Pointed chin þ   þ 25%
Dysplastic ear helices þ    50%
Brachydactyly  þ   15%
Cardiac anomaly     45%
Renal anomaly     15%
Behavioral problems þ  þ þ 75%
Hearing loss
(sensorineural)
    15%
Seizures   þ  25%behaviors such as hand biting, handwringing, and spasmodic self-
hugging, and bouncing when excited. Several nights a week, he
has sleep problems that include 2–3 hr of wakefulness in the
middle of the night. He had aggressive outbursts for which he
received Abilify (15 mg/day), which reduced the frequency
and intensity of the outbursts. At the age of 16 years, he had a
short stature (2 SDs) and macrocephaly (þ2 SDs). Additional
examinations, including a brain magnetic resonance image
(MRI), a metabolic screen of blood and urine, and DNA analysis
of RAI1, revealed no abnormalities.
Individual KS220 was the third child of healthy, unrelated
parents and was born at term after an uneventful pregnancy
with a birth weight of 3,300 g, a length of 51 cm, and a head
circumference of 36 cm. At the age of 5 months, she developed
a pyelonephritis. Her development was severely delayed: At the
age of 19 months, her mental development was that of a
12-month-old, and at 4.5 years of age, her development was that
of a 2.8-year-old and she attended a special school. Autism spec-Thetrum disorder was diagnosed, and she had sleeping difficulties.
When she was 5 years and 11 months old, a clinical examination
revealed that she had a weight of 15.4 kg (0 SDs), a height of 99 cm
(3.5 SDs), and an OFC of 50 cm (0.5 SDs). Additional investiga-
tions comprising EEG, a brain MRI (at the age 7 of months), and
abdominal and cardiac ultrasounds revealed no abnormalities.
A screen for metabolic abnormalities and methylation analysis
for Angelman and Prader-Willi (MIM 176270) syndromes were
normal.
Next-Generation Sequencing
Targeted sequencing was performed on five KSS individuals. The
enriched genes were selected from the AmiGO Gene Ontology
database (see Web Resources) and comprised all genes annotated
with the GO term ‘‘chromatin modification’’ and EHMT1 interac-
tors known from the STRING database (seeWeb Resources). A total
of 316 genes (Table S1, available online) were targeted on a 385K
sequence capture array (Roche NimbleGen). The array design
comprised all coding exons, including surrounding sequences to
cover the splice sites. In total, the design included 4,658 targets
comprising 1,429,871 bp. Sequence capture and posthybridiza-
tion ligation-mediated PCR were done according to the manufac-
turer’s (Roche NimbleGen) instructions with the Titanium
optimized protocol. The amplified captured samples were used
as input for emulsion PCR (emPCR) amplification and subsequent
sequencing with the use of a Roche 454 GS FLX Titanium
sequencer. Data analysis was done with Roche Newbler software
(v.2.3) and the human genome build hg18 (NCBI Build 36.1).
Mapping and coverage statistics were extracted with custom soft-
ware (Table S2). Sequence variations were automatically detected
during mapping, and they were annotated with known RefSeq
genes (UCSC hg19, see Web Resources) and SNP information
(dbSNP129) with the use of in-house analysis software.11
A SOLiD optimized SureSelect Human All Exon Kit (50 Mb,
~21,000 genes; Agilent Technologies) and 3 mg genomic DNA
were used for exome sequencing on four trios of parents and their
affected children. Library preparation was performed as described
previously.12 To allow formultiplexing, we used posthybridization
sample barcodes (Agilent Technologies). Enriched exome libraries
were pooled in equimolar sets of four on the basis of a combined
library concentration of 0.7 pM. Subsequently, the obtained
pool was used for emPCR and bead preparation with the EZbead
system (Life Technologies) and for subsequent sequencing with
a SOLiD 4 system (Life Technologies). Mapping and variant calling
were performed as described previously (Table S3).13
For both targeted and exome sequencing, variants and indels
were selected with the use of strict quality-control settings,
including the presence of at least four (unique) variant reads and
at least 15% variant reads. On average, 2,474 and 21,895 variants
per proband were annotated for targeted sequencing and exome
sequencing, respectively (Table 2).11,12 For variant prioritization,
all nongenic, intronic (other than canonical splice sites), and
synonymous variants were excluded, resulting in an average of
94 (targeted) and 5,596 (exome) variants per sample (Table 2).
Next, all variants from either dbSNP (dbSNP129 [targeted] or
dbSNP132 [exome]) or our in-house database were excluded,
reducing the number of variants to an average of 9 (targeted)
and 167 (exome) (Table 2). On the basis of the knowledge that
KSS is an autosomal-dominant disease caused by de novo muta-
tions, an autosomal-dominant model of inheritance was used for
further prioritization, and all inherited variants except for the
X-linked changes were excluded. X-linked changes were onlyAmerican Journal of Human Genetics 91, 73–82, July 13, 2012 75
Table 2. Prioritization of Detected Variants in Targeted and Exome NGS
Sample
Targeted NGS Family-Based Exome Sequencing
KS113 KS47 KS35 KS94 KS129 Trio KS78 Trio KS220 Trio KS53 Trio KS49
High-confidence variant calls 2,495 2,452 2,403 2,530 2,488 24,604 19,610 20,858 22,511
After exclusion of nongenic, intronic,
and synonymous variants
90 98 81 88 102 6,244 5,182 5,424 5,638
After exclusion of known variants 7 14 7 9 10 158 112 299 98
After exclusion of inherited variants      4 5 9 3
Confirmed by Sanger sequencing 5 6 3 5 4 1 3 0 0
De novo mutations 1 1 0 0 0 1 3 0 0
The following abbreviation is used: NGS, next-generation sequencing.excluded when they were present in the paternal DNA. For the
trios examined by exome sequencing, inherited variants were
excluded by the selection of variants that were only present in
the child but not the parents; this resulted in an average number
of five potential de novo variants per proband. Of these, one
variant, on average, was confirmed to be de novo by Sanger
sequencing. For targeted sequencing, the absence of parental
next-generation sequencing (NGS) data required validation by
Sanger sequencing for all variants. Confirmed variants (Tables S4
and S5) were subsequently analyzed in the parental DNA for the
determination of the mode of inheritance. On average, five vari-
ants were confirmed by Sanger sequencing; of these five, zero to
one variant per sample could be proven to be de novo (Table 2).
To further explore the pathogenicity of the de novo variants, we
evaluated data from in silico resources. These comprised the
genomic evolutionary conservation score (phyloP) as well as Poly-
Phen-2 and SIFT (see Web Resources), which predict the impact of
amino acid substitutions on protein structure and function.
Haplotype Analysis with Short-Tandem-Repeat
Markers
Primers to amplify polymorphic short-tandem-repeat markers in
7q36weredesignedwith thePrimer3program(seeWebResources).
AnM13 tail was added to the 50 and 30 ends of the primers. Markers
were amplified with an M13 forward primer labeled with one of
the fluorophores—FAM, VIC, NED, or ROX—at the 50 end and
a M13 reverse primer with a 50-GTTTCTT-30 added to its 50 end to
reduce tailing. Markers and primer sequences used for haplotype
analysis are shown in Table S6. Final PCR products were mixed
with eight volumes of formamide and half a volume of Genescan
500 (250) LIZ Size Standard and were analyzed with the ABI
PRISM 3730 DNA analyzer (Applied Biosystems). The results were
evaluated by Genemapper (Applied Biosystems).
Genetic Interaction Studies
We performed genetic interaction studies on Drosophila by using
the UAS/Gal4 ectopic expression system14 to induce overexpres-
sion or RNAi-mediated knockdown15 of gene orthologs implicated
in KSS. Gene orthologs were identified by the reverse BLAST
method16 and analysis of the treefam database.17 For MLL3,
SMARCB1, and MBD5, clear orthologs (trr, snr1, and sba, respec-
tively) were identified. NR1l3 is formally orthologous to HR96
because it is monophyletic in phylogenetic analyses.17 However,
it is quite unlikely that the two proteins that they encode are func-
tionally equivalent. HR96 has acquired an internal repeat,18 which76 The American Journal of Human Genetics 91, 73–82, July 13, 2012is not seen in NR1I3. This results in a lack of homology in the
middle section of the proteins. In contrast, the ecdysone receptor
(EcR) is homologous to NR1I3 across the entire length of the
protein and has a much higher similarity than does HR96. Protein
BLASTof NR1I3 against theDrosophila genome gives EcR as the top
hit in Drosophila melanogaster. We therefore conclude, on the basis
of domain composition and amino acid similarity, that EcR is the
best candidate to be used for functional studies.
Fly stocks were obtained from the BloomingtonDrosophila Stock
Center (Indiana University) and the Vienna Drosophila RNAi
Center (Institute for Molecular Pathology).15 For a complete list
of publically available stocks that were used, see Table S7. UAS-
EHMT flies were described previously.19 For genetic interaction
studies, females of the genotypes MS1096-Gal4 and MS1096-
Gal4/FM7d; UAS-EHMT were crossed to fly stocks indicated in
Table S7. Wing phenotypes were examined in female progeny.Results
Identification of De Novo Mutations in Epigenetic
Regulators in Four Individuals with KSS
To identify mutations in our EHMT1-negative cohort of
individuals with KSS (Table 1, Subjects and Methods), we
used two strategies. Five individuals were analyzed by a tar-
geted approach in which genes involved in chromatin
modification were sequenced. Because the targeted
approach could limit the possibility of mutation discovery,
four other individuals and their healthy parents were
analyzed by whole-exome sequencing. The retrieved vari-
ants were filtered as described previously so that potential
disease-causing mutations could be identified.12 All vari-
ants remaining after filtering were analyzed by Sanger
sequencing, which revealed six de novo mutations in
four individuals (Tables S4 and S5). Of these six mutations,
none were observed in our in-house exome-sequencing
database (450 individuals). One, identified in POF1B
on the X chromosome, was found once in the 8,760 alleles
reported in the National Heart, Lung, and Blood Institute
(NHLBI) database (Web Resources), which contains data
from more than 5,300 exomes (>10,600 alleles), leaving
five unique de novo changes identified in this study
(Table 3).















MLL3 KS113 female NM_170606.2 c.4441C>T p.Arg1481* 6.2 damaging deleterious trimethylates histone H3 at
lysine 4 (H3K4me3); central
component of the ASC-2
complex
SMARCB1 KS47 female NM_003073.3 c.110G>A p.Arg37His 6.88 probably
damaging
deleterious member of the SWI/SNF family
of ATP-dependent chromatin-
remodeling complexes
MBD5 KS78 male NM_018328.4 c.150del p.Thr52Hisfs*31 3.64  deleterious contains a methyl-binding
domain that is required
for localization to chromatin
MTMR9 KS220 female NM_015458.3 c.310T>G p.Ser104Ala 2.09 benign tolerated myotubularin-related protein
that is atypical because
it has no dual-specificity
phosphatase domain
NR1I3 KS220 female NM_001077482.2 c.740T>C p.Phe247Ser 3.61 probably
damaging





The following abbreviations are used: NGS, next-generation sequencing; and SWI/SNF, switch/sucrose nonfermentable.
aNucleotide positions of variants are based on GRCh37/hg19.Targeted NGS of individual KS113 revealed a nonsense
mutation (c.4441 C>T [p.Arg1481*]) in the myeloid/
lymphoid or mixed-lineage leukemia 3 gene MLL3
(NM_170606.2) (Figure 1A, Table 3, and Figure S1A). The
father of individual KS113 was deceased, but we could
confirm the absence of this mutation in the mother and
two healthy sisters, who each carried the same paternal
haplotype at the MLL3 locus as KS113 (Figure S2). This
suggests that the mutation occurred as a de novo event.
A single SMARCB1 missense mutation (c.110G>A
[p.Arg37His]; NM_003073.3), predicted to be deleterious,
was detected by targeted NGS in individual KS47 and
was absent in both parents (Figure 1B, Table 3, and
Figure S1B). Interestingly, mutations in this gene as well
as in several other genes that encode proteins of the
SWI/SNF complex were recently reported to cause Coffin
Siris syndrome (CSS [MIM 135900]).20,21 The core pheno-
type of CSS is characterized by ID, coarse facial features,
microcephaly, and a hypoplastic nail of the fifth finger
and/or toe, but the phenotype is also heterogeneous.
Germline mutations in SMARCB1 have also been reported
to predispose to familial schwannomatosis (MIM 162091)
and meningiomas (MIM 607174), but not to ID.22–24
However, these tumor-associated mutations are typically
loss-of-function alleles, and complete loss of SMARCB1
expression is seen in tumors after inactivation of the
second allele.25 In contrast, fibroblasts from individual
KS47 equally expressed wild-type and mutant alleles
(Figure S3), suggesting that substitution of the highly
conserved arginine by histidine in individual KS47 might
cause altered protein function rather than loss of function.
The SMARCB1 mutations identified in CSS are either
missense or in-frame deletions, which suggests that theTheCSS phenotypemight also result from altered protein func-
tion.20 However, the CSS-causing mutations are located at
theC-terminusof theprotein in, or verynear, the conserved
SNF5 domain, whereas the mutation that we identified
is close to the N-terminus of the protein and is not
located in or near a conserved domain. The different loca-
tions of these mutations within SMARCB1 might explain
the differences in phenotype; however, more mutations
will need to be identified before a true genotype-phenotype
correlation can be made. All together, these data suggest
that, depending on the nature of the mutation, altered
SMARCB1 function can lead to diverse forms of ID.
Individual KS78 contains a MBD5 frameshift mutation
(c.150del [p.Thr52Hisfs*31]; NM_018328.4) that results
in a premature stop codon (Figure 1C, Table 3, and
Figure S1C). Deletions encompassing MBD5, as well as
intragenic MBD5 deletions, have previously been identi-
fied in cases with a phenotype reminiscent of Smith-
Magenis syndrome, which is characterized by ID, facial
dysmorphisms, epilepsy, and behavioral problems.26–28
Individual KS78 with the MBD5 frameshift mutation
shows a striking phenotypic overlap with these individ-
uals, underscoring the previously observed phenotypic
similarity between KSS and Smith-Magenis syndrome.5
Analysis of individual KS220 (Figure 1D) revealed three
de novo mutations (Table S5): a splice mutation (c.1318-
1G>C) affecting POF1B, a missense mutation (c.310T>G
[p.Ser104Ala]; NM_015458.3) affecting MTMR9, and
a missense mutation (c.740T>C [p.Phe247Ser]) affecting
NR1I3. The POF1B mutation is found in the NHLBI data-
base and is unlikely to cause KSS because homozygous
mutations in this gene have been reported to cause
premature ovarian failure (MIM 300604) and becauseAmerican Journal of Human Genetics 91, 73–82, July 13, 2012 77
heterozygous carriers have no apparent phenotype.29 This
leaves two unique de novo variants, one in MTMR9 and
one inNR1I3 (Table 3). The amino acid change p.Ser104Ala
caused by theMTMR9mutation is considered to be benign
by PolyPhen-2 and tolerated by SIFT. Intragenic SNPs in
MTMR9 have been associated with obesity (MIM
606641).30 The p.Phe247Ser substitution caused by the
NR1I3 (NM_001077482.2) mutation (Figure 1D and
Figure S1D) is predicted to have a damaging effect on
protein function by both SIFT and PolyPhen-2.
In contrast to their function in neurodevelopment, the
biochemical functions of the genes with de novo muta-
tions are well characterized. MLL3 trimethylates histone
H3 at lysine 4 (H3K4me3) and is a central component of
the activating signal cointegrator-2 (ASC-2) complex
ASCOM, which acts as a transcriptional coactivator for
nuclear hormone receptors.31,32 SMARCB1 is a member
of the switch/sucrose nonfermentable (SWI/SNF) family
of ATP-dependent chromatin-remodeling complexes,
which affect transcription by destabilizing histone-DNA
interactions and altering nucleosome positions.33 MBD5
and its paralog MBD6 contain a methyl-binding domain,
which is required for their localization to chromatin.34
MTMR9, encoded by one of two genes with a unique de
novo mutation in individual KS220, contains a domain
that putatively interacts with SET domains, one of which
is present in EHMT1. However, MTMR9 is cytoplasmic,
and no functional relationship with chromatin regulators
has been reported.35 The other mutated gene in individual
KS220, NR1I3, has been extensively studied in liver
metabolism, but this gene is also expressed in the
brain.36,37 NR1I3 is a nuclear hormone receptor that affects
chromatin structure through recruitment of chromatin-
modifying complexes. Given the predicted damaging
function of the NR1I3 DNA variant (in contrast to the
benign prediction of the MTMR9 mutation) and the
epigenetic role of the encoded protein, we considered
this mutation to be the most likely cause of KSS in indi-
vidual KS220.
Subsequently, we sequencedMBD5, NR1I3, andMLL3 in
a cohort of 50 additional individuals with KSS. No patho-
genic sequence changes were identified, which most likely
reflects the genetic heterogeneity in KSS.
Identification of Functional Connections between
EHMT1, MLL3, SMARCB1, NR1I3, and MBD5
To address the functional relevance of the five identified
genes (MLL3, SMARCB1, MBD5, NR1I3, and MTMR9)
with de novo mutations and to further investigate their
biological relationship with EHMT1, we conducted
genetic interaction studies in Drosophila. We carried out
our experiments by modulating gene expression in the
Drosophila wing, a well-established system for genetic
interaction studies.38 Overexpression of Drosophila EHMT
in the wing consistently causes extra veins in defined
regions of the wing (Figures 2A and 2B). We tested whether
and how genetic manipulation ofMBD5,MLL3, SMARCB1,78 The American Journal of Human Genetics 91, 73–82, July 13, 2012NR1l3, and MTMR9 homologs (sba, trr, snr1, EcR, and
CG5026, respectively [see Subjects and Methods]) could
modulate this EHMT-induced wing phenotype. Expression
of sba/MBD5 alone in the wing induced mild ectopic
wing vein formation with about 50% penetrance
(Figure 2C). When sba/MBD5 was overexpressed together
with EHMT, the EHMT phenotype was strongly enhanced,
and this resulted in a consistent disruption of vein
patterning and a strong increase in ectopic vein formation
(Figure 2D). Thus, EHMT and sba induce similar mild vein
phenotypes in the fly wing, and the strongly increased
phenotypic severity elicited by their co-overexpression
indicates that the two genes genetically interact in a syner-
gistic manner. For the MLL3 ortholog trr, we observed
a striking genetic interaction with EHMT upon RNA inter-
ference (RNAi)-induced knockdown. Trr knockdown alone
in the fly wing causes a mild phenotype consisting of
a mild loss of wing veins and mild upward curvature of
the wing (Figure 2E). Combining trr/MLL3 knockdown
with EHMT overexpression resulted in fully penetrant
pupal lethality resulting from necrosis of the entire devel-
oping wing tissue (Figure 2F). This dramatic compound
phenotype indicates an antagonistic relationship between
trr/MLL3 and EHMT given that knockdown of trr/MLL3
dramatically enhances the EHMT overexpression pheno-
type. We also attempted to examine interaction of
EHMT with snr1/SMARCB1. However, knockdown of
snr1/SMARCB1 in the wing causes an extremely severe
phenotype on its own, which precludes conclusions about
potential genetic interactions with EHMT. Finally, we
investigated genetic interactions with EcR/NR1l3 and
CG5026/MTMR9, which both contain de novo missense
mutations in individual KS220 (Table 3). Quantification
of ectopic wing vein formation (Figure 2G) revealed no
effect of CG5026/MTMR9 knockdown on the EHMT over-
expression phenotype (Figure 2H), consistent with the
notion that the MTMR9 mutation does not cause KSS. In
sharp contrast, the EHMT overexpression phenotype was
almost completely rescued by heterozygous loss-of-func-
tion mutations in EcR/NR1I3 (Figure 2H), suggesting that
EHMT requires EcR/NR1I3 for its activity. Moreover, over-
expression of EcR enhanced EHMT-induced ectopic vein
formation (Figure 2H), providing strong evidence of
a synergistic relationship between EHMT and EcR/NR1I3.
These data further suggest that mutations in NR1I3, not
MTMR9, cause KSS.Discussion
We have identified four genes—MLL3, SMARCB1, MBD5,
and NR1I3—with de novo mutations in individuals with
severe ID and with additional clinical features that closely
resemble those caused by EHMT1 defects. For three of
these genes (MLL3, MBD5, and NR1I3), we were able to
provide evidence of functional cooperation with EHMT1
by using genetic interaction experiments in Drosophila
Figure 2. Drosophila Orthologs of MBD5, MLL3, and NR1I3 Interact Genetically with EHMT
(A) The morphology of the wild-type Drosophila wing is defined by five longitudinal veins (L1–L5) and the anterior and posterior cross
veins (a-cv and p-cv).
(B) Tissue-specific overexpression of UAS-EHMT in the Drosophilawing with the use ofMS1096-Gal4 causes ectopic wing vein formation
between L2 and L3 in 91% of wings and between the p-cv and L5 in 88% of wings (arrows).
(C) Expression of sba/MBD5 with UAS-sba in the fly wing induced mild ectopic wing vein formation posterior to L5 with about 50%
penetrance (arrow).
(D) In combination with UAS-EHMT, this phenotype was severely enhanced, resulting in a highly consistent disruption of normal L5
formation and a massive increase in ectopic vein formation between L2 and L3 in all wings examined (arrows).
(E) RNAi-mediated knockdown of trr/MLL3 by induced expression of an inverted repeat (IR) producing double-stranded RNA homolo-
gous to trr (UAS-trrIR) caused mild loss of wing vein L5 and a slight upward curvature of the wing.
(F) In combination with UAS-EHMT, UAS-trrIR induced pupal lethality caused by the formation of black necrotic tissue in the developing
wing (arrowhead). Identical results were obtained with two individual UAS-trrIR lines (Table S7). Data is shown for UAS-trrIR1.
(G) EHMT-induced ectopic wing vein formation between L2 and L3 is variable in severity and can be quantified accordingly into wild-
type, mild, medium, and strong.
(H) The effect of UAS-EHMT expression on ectopic vein formation in this region is rescued by RNAi-mediated knockdown of EHMTwith
the use of UAS-EHMTIR1. Similar results were obtained with two other EHMT RNAi constructs (Table S7). In contrast, CG5026/MTMR9
knockdown had no effect on the EHMT-induced phenotype, as observed with three individual UAS-CG5026IR lines (Table S7). Loss-
of-function mutations in EcR were able to rescue EHMT-mediated ectopic vein formation, indicating that EcR is required for this
EHMT-induced phenotype. Similar data were obtained with the EcRQ50st allele, the EcRM554fs allele, and two EcR RNAi lines (Table S7).
Overexpression of EcR isoform A caused very mild induction of ectopic vein formation. However, in combination with UAS-EHMT,
UAS-EcR-A strongly enhanced EHMT-induced ectopic vein formation. Similar results were obtained by overexpression of the other
EcR isoforms, B1 and B2.(Figures 2 and 3). However, the severe phenotype of the
SMARCB1-mutant fly precluded testing for genetic inter-
actions. The established genetic interactions appear to be
very specific and thus indicative of a true biological rela-
tionship given that a number of other chromatin-related
molecules and transcription factors such as E(z), esc,
Mier1/CG1620, and FoxG/slp2 did not genetically interact
with EHMT in our assay (data not shown). Furthermore,
no interaction was found with MTMR9, one of three
de novo mutated genes in individual KSS220. Drosophila
genetic interaction studies with established disease genes
thus provide an efficient and, in our opinion, urgently
required method of discriminating between rare or even
unique benign DNA variants and causative mutations in
the NGS era.
In addition to the genetic interactions established
here, complementary evidence of molecular interactionsThebetween MLL3/trr, SMARCB1/snr1, and NR1I3/EcR is
available. MLL3, a critical subunit of the ASCOM coacti-
vator complex,28 and SMARCB1, a core component of
an ATPase-dependent SWI/SNF chromatin-remodeling
complex,33 are important mediators of epigenetic regula-
tion in association with nuclear-receptor transactivation
and directly interact to mediate crosstalk between the
two complexes in which they reside.32,39 NR1I3 was iden-
tified as one of the nuclear receptors that directly associates
with the ASCOM complex.39 SMARCB1 and NR1I3 have
both been shown to interact with nuclear receptor core-
pressor 1 (NCOR1).40,41 In addition, the closest Drosophila
homolog of NR1I3, EcR, was shown to interact both phys-
ically and genetically with the Drosophila ortholog of
MLL3, trr, indicating that the mechanisms of nuclear-
receptor-mediated transcriptional activation are conserved
between mammals and flies.42 These data indicate thatAmerican Journal of Human Genetics 91, 73–82, July 13, 2012 79
Figure 3. An Epigenetic Network Underlying KSS
Functional studies indicate that genes implicated in KSS occur in
a common chromatin-regulating module. This evidence comes
from investigation of direct protein-protein interactions (solid
lines) and from genetic interaction studies with Drosophila mela-
nogaster (dashed lines). Green dashed lines indicate a synergistic
interaction, and red dashed lines indicate an antagonistic interac-
tion. It has been demonstrated in this study that Drosophila EHMT
interacts genetically with sba/MBD5, trr/MLL3, and EcR/NR1I3
(GI1, GI2, and GI3, respectively). Previously, genetic and physical
interactions between trr and EcR (GI4 and DPI1, respectively), as
well as physical association between SMARCB1 and MLL3
(DPI2), have been demonstrated.32,42MLL3, SMARCB1, and NR1I3 cooperate with each other in
the regulation of gene transcription (Figure 3).
The molecular and here demonstrated functional rela-
tionships between EHMT1 and the other four epigenetic
regulators are mirrored by the phenotypic similarities
among individuals containing a de novo mutation in
any of the five different genes. This leads us to propose
a chromatin-modification module, defined by synergistic
and antagonistic interactions, that underlies KSS (Figure 3).
Further genetic studies in KSS individuals with intact
EHMT1, MLL3, SMARCB1, MBD5, and NR1I3 will most
likely reveal additional members of this module. Extension
of the KSS chromatin-modification module might also be
achieved by the consideration of genes implicated in over-
lapping phenotypes. This is exemplified in this study
through the identification of a mutation in MBD5, a gene
that is also disrupted in individuals with 2q23.1-deletion
syndrome (MIM 156200), which is reminiscent of Smith-
Magenis syndrome.27 Smith-Magenis syndrome and KSS
indeed have remarkably overlapping features.6 Most cases
of Smith-Magenis syndrome are caused by haploinsuffi-
ciency of RAI1, which encodes a transcription factor
that acts in conjunction with chromatin-remodeling
complexes.43,44 Finally, other proteins might be added to
the module on the basis of established functional relation-
ships despite the fact that mutations in the corresponding
genes give rise to disorders with little clinic overlap. This
was exemplified in this study through the identification
of amissensemutation in SMARCB1, which is alsomutated
in Coffin-Sirus syndrome, another genetically and pheno-
typically heterogeneous form of syndromic ID. Other
examples include the histone demethylase JARID1C and
the transcriptional regulator MED12, which both contain
mutations in nonsyndromic ID or ID syndromes without80 The American Journal of Human Genetics 91, 73–82, July 13, 2012obvious overlapping features.45,46 However, these epige-
netic regulators both have molecular connections to the
RE1-silencing transcription factor (REST; also known as
NRSF [neuron-restrictive silencer factor]) and to the
EHMT1 paralog G9a/EHMT2.47,48 It is therefore tempting
to speculate that a broader spectrum of ID conditions is
linked to the core KSS chromatin module.
The identification of a chromatin-modification module
underlying ID is of particular interest given recent
evidence showing that epigenetic processes are important
in acute cognitive functioning.4 Adult rescue of cognitive
deficits has been accomplished in several animal ID
models,42–51 including EHMT-mutant flies,19 raising hope
that cognition can be improved postnatally. Further dissec-
tion of the KSS chromatin-regulating module through
mechanistic studies and continued elucidation of its
genetic etiology might allow for fundamental insights
and for the identification of drugs that improve cognition
in this group of genetically heterogeneous but phenotypi-
cally similar individuals. In this respect, we note that
a number of the ID-associated epigenetic regulators, such
as MLL3 and SMARCB1, have also been linked to
cancer.23,52 Research into the associated tumorigenic path-
ways and their applicable drugs might be relevant to neu-
rodevelopmental pathways as well, as was recently shown
for topoisomerase inhibitors in a mouse model for Angel-
man syndrome.53
In summary, the work presented here defines and
characterizes an epigenetic module underlying human
cognitive disorders and underscores the importance of
tight epigenetic control mechanisms in higher brain
function. In addition, the identification of an EHMT-associ-
ated epigeneticmodule, including antagonistic players that
could serve as potential drug targets, is a step toward devel-
oping a strategy to correct for cognitive deficits associated
with this genetically heterogeneous group of ID disorders.Supplemental Data
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